Skip to main content

Schedule of DCTD Presentations at the 2026 American Association for Cancer Research Annual Meeting

DCTD-supported research will be presented at the AACR Annual Meeting from April 17-22, 2026 in San Diego, California. The following tables contain oral and poster presentations with DCTD staff speakers and co-authors.

Oral Presentations

Date/Time	*Title/DCTD Speaker**	ID
April 18 10:51 AM - 11:01 AM	Safety of Prolonged Checkpoint Inhibitor Exposure in Alveolar Soft Part Sarcoma (ASPS) Patients *Alice P. Chen, MD, Nancy Moore, RN, Jared Foster, PhD, Christina Rosenberger, PhD, James H. Doroshow, MD	CT004
April 19 2:30 PM - 3:30 PM	NCI Drug Development Resources and Grant Writing Strategies for New and Early-Stage Investigators Rosemarie Aurigemma, PhD, Christophe Marchand, PhD, Sundar Venkatachalam, PhD, Morgan O’Hayre, PhD, *Yali Fu, PhD	NIH02
April 21 2:30 PM - 3:30 PM	NCI/NIH Opportunities in Funding: NCI-Cancer Diagnosis Program Initiatives and Biospecimen Resources for Investigators Aniruddha Ganguly, PhD, Lokesh Agrawal, PhD, *Ana I. Robles, PhD	NIH09

Poster Presentations

Date/Time	Title/DCTD Presenter (If Applicable)	ID
April 20 2:00 PM - 5:00 PM	Interleukin-1 upregulates dual oxidase 2 expression and ROS production in human pancreatic cancer cells in a STAT1/STAT3-dependent manner	2881/21
	IL-1 beta/ IL-6 co-stimulation synergistically mediates DUOX2/DUOXA2 complex up-regulation via JAK/STAT and p38 signaling events	3319/26
April 21 9:00 AM - 12:00 PM	HDAC inhibitors induce NOX5 expression in human uveal melanoma cells in a Brd4-Sp1/Sp3-dependent manner Smitha Antony, PhD	4491/10
	Advancing new rational drug combinations to treat mutant KRAS-driven pancreatic adenocarcinoma	4473/21
April 21 2:00 PM - 5:00 PM	Heat shock protein inhibitors suppress cytokine-induced DUOX2 mRNA and protein expression in human pancreatic cancer cells in a JAK, STAT dependent manner	6578/11
	DUOX2 is finely tuned by synergism between cytokines IL-6, IL-22, IL-17A, and TNFα in colon cancer	6585/18
	Pilot study of pidnarulex pharmacodynamics in patients with advanced solid tumors Jibran Ahmed, MD	CT293/27
	Development of pancreatic and colon patient-derived xenograft (PDX) tumor microarrays (TMAs) from the NCI patient derived models repository	6061/7
	Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial (RARE 3): Tiragolumab + Atezolizumab	CT259/24
	HPV+ and HPV- head and neck cancer patient-derived models in the NCI Patient-Derived Models Repository	6067/13
April 22 9:00 AM - 12:00 PM	Synergistic cytotoxicity through combination of DNA methyltransferase (DNMT) inhibitors in cancer cells	7067/14

Meet-the-Expert Presentations

Date/Time	Topic	Presenter
April 20 1:30 PM - 2:00 PM	Early-Stage Investigator Policy & R37 Extension Process	Aniruddha Ganguly, PhD Cancer Diagnosis Program
April 21 10:30 AM - 11:00 AM	DCTD’s Investigative Toxicology Laboratory: Early and Late-Stage Drug Development	Elizabeth Glaze, PhD Developmental Therapeutics Program
April 21 1:30 PM - 2:00 PM	NCI Integrative Medicine Cancer Therapeutics Portfolio and Funding Opportunities-Lifestyle Modification and Microbiome	Dani Xi, PhD Office Of Cancer Complementary and Alternative Medicine